eligibility_summary
Adults (≥18) with HIV and R/R aggressive B‑cell NHL (DLBCL/HGBCL/PMBCL/FL3B) after ≥2 lines incl anthracycline+anti‑CD20, PET+ or marrow disease, ECOG 0–1, adequate organs/counts, vascular access, CD19+ if prior CD19 therapy, on ART with VL <50, HBV/HCV allowed if controlled, contraception required. Exclude CNS‑only disease, high auto‑HSCT benefit, uncontrolled/recent opportunistic infection, recent prohibited therapy/steroids/radiation, prior CAR‑T, major cardiac/CNS disease, pregnancy, unresolved ≥G2 tox.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, single-arm study in adults with well-controlled HIV and relapsed/refractory aggressive B-cell NHL. Interventions: 1) Axicabtagene ciloleucel (Yescarta) — autologous anti-CD19 CAR-T cell therapy. Patient T cells are engineered to express a CAR with anti-CD19 scFv and CD28/CD3ζ signaling domains, binding to CD19 activates cytotoxic T-cell killing and expansion against CD19-positive B-cell lymphoma. 2) Lymphodepleting chemotherapy: cyclophosphamide (alkylating agent causing DNA crosslinks) and fludarabine (purine analog antimetabolite inhibiting DNA synthesis). These reduce endogenous lymphocytes/immunosuppressive cells to support CAR-T engraftment. Targets: CD19 on malignant B cells, T-cell activation (CD28/CD3ζ), transient host lymphocyte depletion.